Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 17.7B | 33.3% |
| Gross Profit | 8.98B | 84.2% |
| Cost of Revenue | 8.72B | 3.7% |
| Operating expense | 6.21B | 23.1% |
| Net Income | 4.47B | 10790.2% |
| EBITDA | 6.78B | 241.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 219B | 1.6% |
| Total Liabilities | 127B | 1% |
| Total Equity | 92.3B | 5.2% |
| Shares Outstanding | 5.67B | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 6.71B | 477% |
| Cash from investing | -2.06B | 144.7% |
| Cash from financing | -4.64B | 88.5% |
EPS
Financial Highlights for Pfizer in Q3 '24
Pfizer reported a revenue of 17.7B, which is a 33.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 8.98B, marking a 84.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 8.72B, a 3.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 6.21B, showing a -23.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 4.47B, showing a 10790.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 6.78B, showing a 241.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Pfizer with growth in revenue, gross profit, and net income.
